Get the Stockscreener App
6.54
4.31%
0.27
After Hours:
6.43
-0.11
-1.68%
Cingulate Inc stock is traded at $6.54, with a volume of 276.08K.
It is up +4.31% in the last 24 hours and up +7.04% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$6.27
Open:
$6.07
24h Volume:
276.08K
Relative Volume:
1.07
Market Cap:
$48.70M
Revenue:
-
Net Income/Loss:
$-22.06M
P/E Ratio:
-1.2369
EPS:
-5.2876
Net Cash Flow:
$-17.93M
1W Performance:
+7.39%
1M Performance:
+7.04%
6M Performance:
+75.34%
1Y Performance:
+58.74%
1-Day Range:
$5.95
$6.69
1-Week Range:
$5.91
$7.15
52-Week Range:
$3.20
$7.92
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
6.54 | 46.69M | 0 | -22.06M | -17.93M | -5.2876 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate (NASDAQ: CING) vote on 19% share issuance and warrants - Stock Titan
CING Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Highlights: Can Cingulate Inc disrupt its industryDividend Hike & Daily Growth Stock Investment Tips - baoquankhu1.vn
CINGW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Buybacks Report: Does COLAR meet Warren Buffetts criteria2025 Growth vs Value & Accurate Buy Signal Notifications - baoquankhu1.vn
Can Cingulate Inc. Equity Warrant maintain its current growth rate - mfd.ru
What drives Cingulate Inc.’s stock priceJuly 2025 Trade Ideas & Consistent Growth Equity Picks - mfd.ru
Investment deal brings well-known area entrepreneur to Cingulate board - The Business Journals
Activity Recap: What are analysts price targets for Cingulate Inc Equity WarrantQuarterly Growth Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Aug EndMonth: What are analysts price targets for Cingulate Inc Equity WarrantJuly 2025 Update & Accurate Trade Setup Notifications - baoquankhu1.vn
Volatility Watch: What are analysts price targets for Cingulate Inc Equity WarrantJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Cingulate Secures $12 Million PIPE to Advance CTx-1301 - The Globe and Mail
Cingulate Inc. announced that it has received $11.796254 million in funding - marketscreener.com
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Bitget
Cingulate appoints Jeff Hargroves to Board and key committees - TradingView
Investors lock up $12M to back Cingulate’s CTx-1301 launch - Stock Titan
Earnings Beat: What are analysts’ price targets for Cingulate Inc. Equity WarrantPortfolio Performance Report & Free Technical Confirmation Trade Alerts - mfd.ru
What are Cingulate Inc.’s recent SEC filings showingWeekly Trade Summary & Daily Momentum Trading Reports - mfd.ru
Is Cingulate Inc. Equity Warrant stock supported by innovation pipelineMarket Movers & Risk Managed Investment Signals - mfd.ru
Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock - MarketBeat
Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock - MarketBeat
Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares - MarketBeat
Growth Value: Is Cingulate Inc likely to announce a buybackWeekly Market Outlook & AI Powered Market Entry Ideas - baoquankhu1.vn
Weekly Recap: Is CDROW stock a good dividend stockWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Cingulate Advances Capital Raise with Private Placement Financing - TipRanks
ADHD Drug Maker Cingulate Draws Investor Attention; Stock Up Over 60% In Seven Months - RTTNews
How Cingulate Inc. stock reacts to inflationary pressuresWeekly Risk Summary & AI Powered Buy/Sell Recommendations - mfd.ru
Ideas Watch: Is Cingulate Inc in a long term uptrendQuarterly Investment Review & Weekly Momentum Picks - baoquankhu1.vn
Sentiment Watch: Should I average down on Cineverse Corp stockTrade Exit Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Cingulate Announces Private Placement and New Preferred Stock - The Globe and Mail
Cingulate Signs Multiple Material Agreements - TradingView
Cingulate Inc. announced that it expects to receive $12.011001 million in funding - marketscreener.com
What’s Cingulate Inc.’s historical returnTrading Volume Surges & The Smart Money Is Buying These Picks - bollywoodhelpline.com
Aug Patterns: What is the target price for Cingulate Inc Equity Warrant stockJuly 2025 Technicals & Community Verified Watchlist Alerts - baoquankhu1.vn
Is Cingulate Inc. stock attractive after correctionJuly 2025 Action & Accurate Buy Signal Alerts - bollywoodhelpline.com
Market Pulse: What is the target price for Cingulate Inc Equity Warrant stockExit Point & Short-Term Trading Alerts - baoquankhu1.vn
Cingulate (NASDAQ:CING) Trading 3.1% Higher – Should You Buy? - Defense World
Cingulate Expands At-The-Market Equity Offering Capacity - The Globe and Mail
Cingulate increases at-the-market offering limit to $31.9 million By Investing.com - Investing.com Canada
Cingulate increases at-the-market offering limit to $31.9 million - Investing.com
Cingulate Inc. Increases Offering Price Under Sales Agreement - TradingView
Quarterly Recap: Is Cingulate Inc likely to announce a buybackJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Analysis Recap: Why Cingulate Inc stock appeals to analystsForecast Cut & Real-Time Sentiment Analysis - Bộ Nội Vụ
Market Outlook: Will Cingulate Inc Equity Warrant stock remain a Wall Street favoriteJuly 2025 Reactions & High Win Rate Trade Alerts - Bộ Nội Vụ
Cingulate Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing - TradingView — Track All Markets
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
Cingulate price target lowered to $16 from $17 at Roth Capital - MSN
Will Cingulate Inc. stock maintain dividend yieldColor and Style Update & trail grip notes for mixed terrain - ulpravda.ru
Why Cingulate Inc. stock remains a top recommendation2025 Breakouts & Breakdowns & Stepwise Swing Trade Plans - Улправда
What analyst consensus says on Cingulate Inc. stockTake Profit & Safe Entry Zone Tips - Улправда
Market Moves: Will Cingulate Inc. stock gain from lower inflationBond Market & Daily Entry Point Trade Alerts - ulpravda.ru
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):